Category: Gallery

• Quest Diagnostics has introduced the AD-Detect™ Test for Alzheimer’s disease, a blood-based biomarker test available for purchase by consumers.
• The new test allows individuals to gauge their risk of developing Alzheimer’s disease by measuring beta-amyloid protein, a key indicator of the condition.
• With the potential to reshape early detection strategies, this new test aligns with the changing landscape of Alzheimer’s care, helping individuals to proactively manage their cognitive health.

Blood tests have the potential to enhance the accuracy and convenience of diagnosing and tracking Alzheimer’s disease.

With more than 6 million Americans currently affected by the disease, a number projected to rise to almost 13 million by 2050, early detection and intervention are crucial.

Current diagnostic methods, such as MRI scans, cognitive tests, and physical examinations have limitations due to their need for specialized clinics and trained staff.

By improving the accessibility of Alzheimer’s testing, medical professionals could identify the disease earlier and provide interventions to potentially slow progression.

• Quest Diagnostics has introduced the AD-Detect™ Test for Alzheimer’s disease, a blood-based biomarker test available for purchase by consumers.
• The new test allows individuals to gauge their risk of developing Alzheimer’s disease by measuring beta-amyloid protein, a key indicator of the condition.
• With the potential to reshape early detection strategies, this new test aligns with the changing landscape of Alzheimer’s care, helping individuals to proactively manage their cognitive health.

Blood tests have the potential to enhance the accuracy and convenience of diagnosing and tracking Alzheimer’s disease.

With more than 6 million Americans currently affected by the disease, a number projected to rise to almost 13 million by 2050, early detection and intervention are crucial.

Current diagnostic methods, such as MRI scans, cognitive tests, and physical examinations have limitations due to their need for specialized clinics and trained staff.

By improving the accessibility of Alzheimer’s testing, medical professionals could identify the disease earlier and provide interventions to potentially slow progression.

• Quest Diagnostics has introduced the AD-Detect™ Test for Alzheimer’s disease, a blood-based biomarker test available for purchase by consumers.
• The new test allows individuals to gauge their risk of developing Alzheimer’s disease by measuring beta-amyloid protein, a key indicator of the condition.
• With the potential to reshape early detection strategies, this new test aligns with the changing landscape of Alzheimer’s care, helping individuals to proactively manage their cognitive health.

Blood tests have the potential to enhance the accuracy and convenience of diagnosing and tracking Alzheimer’s disease.

With more than 6 million Americans currently affected by the disease, a number projected to rise to almost 13 million by 2050, early detection and intervention are crucial.

Current diagnostic methods, such as MRI scans, cognitive tests, and physical examinations have limitations due to their need for specialized clinics and trained staff.

By improving the accessibility of Alzheimer’s testing, medical professionals could identify the disease earlier and provide interventions to potentially slow progression.

• Quest Diagnostics has introduced the AD-Detect™ Test for Alzheimer’s disease, a blood-based biomarker test available for purchase by consumers.
• The new test allows individuals to gauge their risk of developing Alzheimer’s disease by measuring beta-amyloid protein, a key indicator of the condition.
• With the potential to reshape early detection strategies, this new test aligns with the changing landscape of Alzheimer’s care, helping individuals to proactively manage their cognitive health.

Blood tests have the potential to enhance the accuracy and convenience of diagnosing and tracking Alzheimer’s disease.

With more than 6 million Americans currently affected by the disease, a number projected to rise to almost 13 million by 2050, early detection and intervention are crucial.

Current diagnostic methods, such as MRI scans, cognitive tests, and physical examinations have limitations due to their need for specialized clinics and trained staff.

By improving the accessibility of Alzheimer’s testing, medical professionals could identify the disease earlier and provide interventions to potentially slow progression.